Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Xin Lin,Zaozao Zheng,Junyi Liu,Yujie Chen,Junqiang Ding,Guosheng Hu,Yahong Hu,Suling Liu,Wenxin Luo,Ningshao Xia,Wen Li

DOI: https://doi.org/10.1158/2326-6066.22543596.v1

2023-01-01

Abstract:All Supplementary Figures (1-9)

What problem does this paper attempt to address?

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543596

2023-01-01

Abstract:<p>All Supplementary Figures (1-9)</p>
Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Wenqun Zhong,Zhang Xiao,Zhiyuan Qin,Jingbo Yang,Yi Wen,Ziyan Yu,Yumei Li,Neil C. Sheppard,Serge Y. Fuchs,Xiaowei Xu,Meenhard Herlyn,Carl H. June,Ellen Puré,Wei Guo

DOI: https://doi.org/10.1158/0008-5472.23952936.v1

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.22543587

2023-01-01

Abstract:<p>Supplementary Table 2</p>
Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Lin Xia,Zaozao Zheng,Jun-yi Liu,Yu-jie Chen,Jiancheng Ding,Guo-sheng Hu,Ya-hong Hu,Suling Liu,Wen-xin Luo,Ning-shao Xia,Wen Liu

DOI: https://doi.org/10.1158/2326-6066.cir-20-0405

IF: 10.1

2021-04-19

Cancer Immunology Research

Abstract:Abstract EGFR-targeted chimeric antigen receptor (CAR) T cells are potent and specific in suppressing the growth of triple-negative breast cancer (TNBC) in vitro and in vivo. However, in this study, a subset of mice soon acquired resistance, which limits the potential use of EGFR CAR T cells. We aimed to find a way to overcome the observed resistance. Transcriptomic analysis results revealed that EGFR CAR T-cell treatment induced a set of immunosuppressive genes, presumably through IFNγ signaling, in EGFR CAR T-cell–resistant TNBC tumors. The EGFR CAR T-cell–induced immunosuppressive genes were associated with EGFR CAR T-cell–activated enhancers and were especially sensitive to THZ1, a CDK7 inhibitor we screened out of a panel of small molecules targeting epigenetic modulators. Accordingly, combination therapy with THZ1 and EGFR CAR T cells suppressed immune resistance, tumor growth, and metastasis in TNBC tumor models, including human MDA-MB-231 cell–derived and TNBC patient–derived xenografts, and mouse EMT6 cell–derived allografts. Taken together, we demonstrated that transcriptional modulation using epigenetic inhibitors could overcome CAR T-cell therapy–induced immune resistance, thus providing a therapeutic avenue for treating TNBC in the clinic.

oncology,immunology
Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin,Liang Liu,Yun Xing,Tao Meng,Li Ma,Jinpeng Pei,Ying Cong,Xuesai Zhang,Zhiqiang Ren,Xin Wang,Jingkang Shen,Ker Yu

DOI: https://doi.org/10.1158/1535-7163.22519333

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Methods, Figures S1-14 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

James R. Whittle,François Vaillant,Elliot Surgenor,Antonia N. Policheni,Göknur Giner,Bianca D. Capaldo,Huei‐Rong Chen,He K. Liu,Johanna F. Dekkers,Norman Sachs,Hans Clevers,Andrew Fellowes,Thomas Green,Huiling Xu,Stephen B. Fox,Marco J. Herold,Gordon K. Smyth,Daniel H.D. Gray,Jane E. Visvader,Geoffrey J. Lindeman

DOI: https://doi.org/10.1158/1078-0432.22475475

2023-01-01

Abstract:Supplemental Methods and Figures
Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

Bo Li,Triona Ni Chonghaile,Yue Fan,Stephen F. Madden,Rut Klinger,Aisling E. O'Connor,Louise Walsh,Gillian O'Hurley,Girish Mallya Udupi,Jesuchristopher Joseph,Finbarr Tarrant,Emer Conroy,Alexander Gaber,Suet-Feung Chin,Helen A. Bardwell,Elena Provenzano,John Crown,Thierry Dubois,Sabine Linn,Karin Jirstrom,Carlos Caldas,Darran P. O'Connor,William M. Gallagher

DOI: https://doi.org/10.1158/0008-5472.22414067.v1

2023-01-01

Abstract:Combination treatment with THZ1 and ABT-263 shows synergistic effects in TNBC cells
Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Weiping Peng,Xi Jin,Xiao‐En Xu,Yingju Yang,Ding Ma,Zhi‐Ming Shao,Yi‐Zhou Jiang

DOI: https://doi.org/10.1158/0008-5472.22732543

2023-01-01

Abstract:Supplementary methods, figures, figure legends, and tables
Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Xinyi Tu,Mohamed M. Kahila,Qin Zhou,Jia Yu,Krishna R. Kalari,Liewei Wang,William S. Harmsen,Jian Yuan,Judy C. Boughey,Matthew P. Goetz,Jann N. Sarkaria,Zhenkun Lou,Robert W. Mutter

DOI: https://doi.org/10.1158/1535-7163.22504606

2023-01-01

Abstract:Supplementary Table 4 demonstrates single nucleotide variants, indels, copy number variants and copy number alterations in MCTNBC4
Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Meenakshi Anurag,Eric J. Jaehnig,Karsten Krug,Jonathan T. Lei,Erik J. Bergstrom,Beom-Jun Kim,Tanmayi D. Vashist,Anh Minh Tran Huynh,Yongchao Dou,Xuxu Gou,Chen Huang,Zhiao Shi,Bo Wen,Viktoriya Korchina,Richard A. Gibbs,Donna M. Muzny,Harshavardhan Doddapaneni,Lacey E. Dobrolecki,Henry Rodriguez,Ana I. Robles,Tara Hiltke,Michael T. Lewis,Julie R. Nangia,Maryam Nemati Shafaee,Shunqiang Li,Ian S. Hagemann,Jeremy Hoog,Bora Lim,C. Kent Osborne,D.R. Mani,Michael A. Gillette,Bing Zhang,Gloria V. Echeverria,George Miles,Mothaffar F. Rimawi,Steven A. Carr,Foluso O. Ademuyiwa,Shankha Satpathy,Matthew J. Ellis

DOI: https://doi.org/10.1158/2159-8290.22541898

2023-01-01

Abstract:Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer
Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Yuncheng Bei,Jian He,Xuhui Dong,Yuxin Wang,Sijie Wang,Wan Guo,Chengjie Cai,Zhiye Xu,Jia Wei,Ju Yang,Nan Zhang,Pingping Shen

DOI: https://doi.org/10.1158/0008-5472.23684031.v1

2023-01-01

Abstract:Supplementary Figures and legends
Supplementary Fig. 6 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips,Carter T. Fields,Guangmin Li,Donald Dowbenko,Gabriele Schaefer,Kathy Miller,Fabrice Andre,Howard A. Burris,Kathy S. Albain,Nadia Harbeck,Veronique Dieras,Diana Crivellari,Liang Fang,Ellie Guardino,Steven R. Olsen,Lisa M. Crocker,Mark X. Sliwkowski

DOI: https://doi.org/10.1158/1078-0432.22448925

2023-01-01

Abstract:PDF file 67K, TDM4373g Phase Ib Clinical Study Design
Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Zhen Zhang,Xuan Zhao,Qitai Zhao,Xinfeng Chen,Congcong Li,Yaqing Liu,Chunyi Shen,Lijie Song,Lijun Miao,Fuyou Guo,Xiaoning Mou,Jie Zhao,Weiyue Gu,Yi Zhang

DOI: https://doi.org/10.1158/2326-6066.27951168

2024-01-01

Abstract:Supplementary Figure S7. Basic flow chart of PD-1/CD28-CD19 CAR-PD-1+ T cell therapy.
Supplementary Fig. 5 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Gail D. Lewis Phillips,Carter T. Fields,Guangmin Li,Donald Dowbenko,Gabriele Schaefer,Kathy D. Miller,Fabrice André,Howard A. Burris,Kathy S. Albain,Nadia Harbeck,Véronique Dièras,Diana Crivellari,Liang Fang,Ellie Guardino,Steven R. Olsen,Lisa Crocker,Mark X. Sliwkowski

DOI: https://doi.org/10.1158/1078-0432.22448928.v1

2023-01-01

Abstract:PDF file 238K, Kaplan-Meier plots of time-to-tumor doubling in Calu-3 (A) and KPL-4 (B) xenograft models after treatment with T-DM1 and pertuzumab
Supplementary Data from Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane Via Coordinated Induction of Cell Death Programs

Yongqiang Wang,Zenghong Huang,Christopher Z. Chen,Chengfei Liu,Christopher P. Evans,Allen C. Gao,Fangjian Zhou,Hongwu Chen

DOI: https://doi.org/10.1158/1535-7163.22506840.v1

2023-01-01

Abstract:Supplementary Figures and Tables
Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Lu Xu,Eiki Kikuchi,Chunxiao Xu,Hiromichi Ebi,Dalia Ercan,Katherine A. Cheng,Robert Padera,Jeffrey A. Engelman,Pasi A. Jänne,Geoffrey I. Shapiro,Takeshi Shimamura,Kwok-Kin Wong

DOI: https://doi.org/10.1158/0008-5472.22391819.v1

2023-01-01

Abstract:PDF file - 1.4MB, Supplemental Figure 1. MET is inducible in MET, TD/MET, and TL/MET models Supplemental Figure 2. Quantification of hMET expression in mouse models Supplemental Figure 3. Comparison of the tumor counts in mutant EGFR lung tumors with or without expression of hMET. Supplemental Figure 4. Representative MRI images prior to and after treatment in TL and TL/MET mice. Supplemental Figure 5. Xenografts of HCC827GR6 cells ectopically expressing EGFR E746_A750del/T790M are sensitive to the combination of WZ4002 and 17-DMAG. Supplemental Figure 6. The WZ4002/crizotinib or WZ4002/17-DMAG combinations suppress phosphorylation of EGFR, Akt, and Erk in TD and TD/MET to a greater extent than individual treatments
Supplementary Figure 1 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Lanlan Pang,Yihua Huang,Weitao Zhuang,Yaxiong Zhang,Jun Liao,Yue Hao,Feng Hao,Guoqian Wang,Ze-xin Chase Chen,Yu Zhu,Mengzhen Li,Zhengbo Song,Pengbo Deng,Jing Li,Li Zhang,Wenfeng Fang

DOI: https://doi.org/10.1158/1078-0432.26037501.v1

2024-01-01

Abstract:Supplementary Figure 1. Study design.
Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

Ke‐Da Yu,Rui Zhu,Mei Zhan,Angel Rodriguez,Wei Yang,Stephen T.C. Wong,Andreas Makris,Brian D. Lehmann,Xi Chen,Ingrid A. Mayer,Jennifer A. Pietenpol,Zhi‐Ming Shao,W. Fraser Symmans,Jenny Chang‐Claude

DOI: https://doi.org/10.1158/1078-0432.22446909

2023-01-01

Abstract:Supplementary Figure A1 PDF file 73K, Subgroup analysis of the extended validation cohort

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Figures from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells Against Solid Tumors

Supplementary Table 2 from Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition

Supplementary Figures from Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody–Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Supplementary Methods, Figures S1-14 from Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor–Positive Breast Cancer

Figure S5 from Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer

Supplementary Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Supplementary Table 4 from ATR Inhibition is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Supplementary Figure from Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Supplementary Figures from Targeting CD44 Variant 5 with an Antibody–Drug Conjugate is an Effective Therapeutic Strategy for Intrahepatic Cholangiocarcinoma

Supplementary Fig. 6 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Figure S7 from Peripheral Blood–Derived PD-1/CD28–CD19 CAR–Modified PD-1+ T-Cell Therapy in Patients with Solid Tumors

Supplementary Fig. 5 from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Supplementary Data from Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane Via Coordinated Induction of Cell Death Programs

Supplementary Figures 1-6 from Combined EGFR/MET or EGFR/HSP90 Inhibition is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

Supplementary Figure 1 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Figure A1 from Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer